scholarly journals Use of Low Dose Pregabalin for Attenuation of Hemodynamic Response to Laryngoscopy and Intubation in Treated Hypertensive Patients

2019 ◽  
Vol 2 (2) ◽  
pp. 215-219
Author(s):  
Puja Thapa ◽  
Sunita Panta ◽  
Mallika Rayamajhi ◽  
Santosh Khadka ◽  
Bishwo Ram Amatya ◽  
...  
Keyword(s):  
Low Dose ◽  
Hemodynamic Response ◽  
Sedation Scale ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Randomised Study ◽  
Arterial Blood ◽  
Ramsay Sedation Scale ◽  
Dose Oral ◽  
Baseline Characteristics

Introduction: Laryngoscopy and tracheal intubation are two powerful noxious stimuli that can be potentially deleterious especially in hypertensive patients. This study evaluated the efficacy of low dose oral pregabalin used as a premedication for attenuation of this marked sympathetic response of airway instrumentation.Materials and Methods: This was a double-blind randomised study done at a tertiary level referral hospital. The trial was registered as UMIN-000037103 (https://www.umin.ac.jp/ctr/). Patients were randomly assigned into two groups. Placebo arm received multivitamin capsule and treatment arm received Cap. Pregabalin (75 mg), 60 minutes before the induction of general anesthesia. The level of preoperative sedation was assessed with the Ramsay Sedation Scale. Heart rate, systolic, diastolic and mean arterial blood pressure were monitored and recorded before and during induction, during laryngoscopy and 1, 3 and 5 minutes of intubation.Results: A total of 50 patients, 25 in each arm were enrolled. The baseline characteristics were comparable. SBP was significantly lower in the Pregabalin group than in Placebo at all the periods of recording, however, DBP and MAP decreased significantly during, after 1 and 3 minutes of laryngoscopy (p=0.001). Sedation was significantly better in the Pregabalin group with 86% in RSS 3 compared to 80% of a placebo arm in RSS2 (P <0.001).Conclusions: Premedication with a single oral dose of Pregabalin (75 mg) is effective for sedation and attenuation of hemodynamic response to direct laryngoscopy and endotracheal intubation in controlled hypertensive patients without any side effects.

PREVENTING VENOUS THROMBOSIS (VT) WITH HEPARIN ALONE OR WITH HEPARIN/DIHYDROERGOTAMINE AFTER ELECTIVE HIP REPLACEMENT, A DOUBLE-BLIND, RANDOMISED, VENOGRAM END-POINT COMPARISON

1987 ◽  
Author(s):  
J F Cade ◽  
K W Mills ◽  
A S Gallus ◽  
W Murphy
Keyword(s):  
Venous Thrombosis ◽  
General Surgery ◽  
Hip Replacement ◽  
Low Dose ◽  
Double Blind ◽  
Randomised Study ◽  
Sodium Heparin ◽  
End Point ◽  
Small Doses

Dihydro-ergotaraine (DHE) appears to be synergistic with small doses of hepari when used to prevent VT after general surgery. However, doubt remains whether DHEhas this effect in patients with elective hip replacement (THR). We have therefore compared the results of VT prophylaxis using sub-cutaneous (sc) low-dose heparinalone or sc heparin plus sc DHE in a double-blind, randomised, study of 126 patientshaving elective THR, 98 at centre (1)and 28 at centre (2).All received 5000 iu sodium heparin, hourly for 7 days, starting 2 hours before surgery at centre (1), or immediately after surgery at centre (2). Patients alsoreceived a separate 0.5 ml (0.5 mg) DHEorplacebo injection each time they receivedheparin. Patients had bilateral ascendingvenography on the 7th postoperativeday, and venograms were read before the treatment code was broken.These results do not support the presence of synergism between heparin and DHE in this situation.

A double-blind randomized trial of low-dose oral urea to prevent sickle cell crises

1982 ◽  
Vol 35 (2) ◽  
pp. 151-161 ◽  
Author(s):  
Mitchell Gail ◽  
Janis Beach ◽  
Allison Dark ◽  
Roger Lewis ◽  
Helga Morrow
Keyword(s):  
Randomized Trial ◽  
Sickle Cell ◽  
Low Dose ◽  
Double Blind ◽  
Dose Oral ◽  
Sickle Cell Crises

Clinical Evaluation of Atenolol in Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 513s-515s
Author(s):  
L. Hansson ◽  
B. E. Karlberg ◽  
H. Åberg ◽  
A. Westerlund ◽  
N. C. Henningsen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Blocking Agent ◽  
Long Term Results ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Arterial Blood ◽  
Obstructive Airways Disease ◽  
Blind Comparison

1. Atenolol (ICI 66.082, Tenormin) is a new β-adrenoreceptor-blocking agent, devoid of intrinsic sympathomimetic and membrane-stabilizing properties. It does not cross the blood—brain barrier. 2. Atenolol given to hypertensive patients in initial open trials reduced arterial blood pressure significantly. 3. A double-blind comparison between atenolol and placebo in forty-five patients with essential hypertension demonstrated that atenolol gave a statistically significant reduction of blood pressure (Δ 28/15 mmHg, P < 0·005). 4. The optimum anti-hypertensive dose of atenolol in patients with mild to moderately severe essential hypertension was 200 mg daily. 5. Atenolol was compared with propranolol in thirty patients with essential hypertension. No statistically significant differences of anti-hypertensive effect were observed between the two drugs. 6. Long-term results (up to 2 years) in 117 hypertensive patients indicate that drug tolerance is good. No serious toxic effects were observed. 7. In four of twelve hypertensive patients with obstructive airways disease atenolol had to be withdrawn owing to deterioration of ventilatory function.

Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study

2008 ◽  
Vol 16 (4) ◽  
pp. 225-234 ◽  
Author(s):  
G. Zironi ◽  
C. Rossi ◽  
S. Siringo ◽  
C. Galaverni ◽  
S. Gaiani ◽  
...  
Keyword(s):  
Hemodynamic Response ◽  
Controlled Study ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Short And Long Term

scholarly journals The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics

2021 ◽  
pp. 1-10
Author(s):  
Muh Geot Wong ◽  
Jicheng Lv ◽  
Michelle A. Hladunewich ◽  
Vivekanand Jha ◽  
Lai Seong Hooi ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Kidney Failure ◽  
Trial Design ◽  
Low Dose ◽  
Treatment Algorithm ◽  
Renin Angiotensin System ◽  
Double Blind ◽  
Matching Placebo ◽  
Therapeutic Evaluation ◽  
Baseline Characteristics

<b><i>Introduction:</i></b> Despite optimal current care, up to 30% of individuals suffering from immunoglobulin A nephropathy (IgAN) will develop kidney failure requiring dialysis or kidney transplantation. The Therapeutic Evaluation of STeroids in IgA Nephropathy Global (TESTING) study was designed to assess the benefits and risks of steroids in people with IgAN. We report the trial design as well as the baseline characteristics of study participants. <b><i>Methods:</i></b> It is an investigator-initiated, multicenter, double-blind, placebo-controlled, randomized trial of individuals with kidney biopsy-confirmed IgAN, proteinuria ≥1 g/day, and an estimated GFR of 20–120 mL/min/1.73 m<sup>2</sup>, following at least 3 months of standard of care including maximum labelled (or tolerated) dose of renin-angiotensin system blockade. The original study design randomized participants 1:1 to oral methylprednisolone (0.6–0.8 mg/kg/day, maximum 48 mg/day) for 2 months, with subsequent weaning by 8 mg/day/month over 6–8 months, or matching placebo. The intervention was modified in 2016 (due to an excess of serious infection) to low-dose methylprednisolone (0.4 mg/kg/day, maximum 32 mg/day) for 2 months, followed by weaning by 4 mg/day/month over 6–9 months, or matching placebo. Participants recruited after 2016 also received prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia during the first 12 weeks of treatment. <b><i>Results:</i></b> The study recruitment period extended from May 2012 to November 2019. By the time the excess of serious infections was observed, 262 participants had been randomized to the original full-dose treatment algorithm, and an interim analysis was reported in 2016. Subsequently, 241 additional participants were randomized to a revised low-dose protocol, for a total of 503 participants from China (373), India (78), Canada (24), Australia (18), and Malaysia (10). The mean age of randomized participants was 38, 39% were female, mean eGFR at randomization was 62.7 mL/min/1.73 m<sup>2</sup>, and mean 24-h urine protein 2.54 g. The primary endpoint is a composite of 40% eGFR decline from baseline or kidney failure (dialysis, transplantation, or death due to kidney disease), and participants will be followed until the primary outcome has been observed in at least 160 randomized participants. Analyses will also be made across predefined subgroups. Effects on eGFR slope and albuminuria will also be assessed overall, as well as by the steroid dosing regimen. <b><i>Conclusions:</i></b> The TESTING study (combined full and low dose) will define the benefits of corticosteroid use on major kidney outcomes, as well as the risks of therapy, and provide data on the relative effects of different doses, in individuals with high-risk IgAN.

Sa1977 A Randomised, Double-Blind Study of High and Low Dose Oral Delayed-Release Mesalamine Does Not Demonstrate a Difference in Treating Mild to Moderately Active Ulcerative Colitis in Children

2012 ◽  
Vol 142 (5) ◽  
pp. S-371-S-372
Author(s):  
Harland S. Winter ◽  
Barbara Iwanczak ◽  
Melvin B. Heyman ◽  
Eduardo Ibarguen-Secchia ◽  
Maciej Kaczmarski ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Low Dose ◽  
Blind Study ◽  
Double Blind Study ◽  
Active Ulcerative Colitis ◽  
Double Blind ◽  
Delayed Release ◽  
Dose Oral
Sign in / Sign up

Export Citation Format

Share Document